DMPA, zalcitabine, and the FDA.
D003271:Contraceptive Agents, Female / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008525:Medroxyprogesterone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D014481:United States; D014486:United States Food and Drug Administration; D016047:Zalcitabine / Q000627:therapeutic use*
D003271:Contraceptive Agents, Female; D016047:Zalcitabine; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone